ABOUT US
CONTACT US
FAQ
PRIVACY POLICY
REFUND AND CANCELLATION
BLOGS
COMPANIES
REPORTS
0
U.S. (TOLL FREE)
+1 (315) 215-3225
Automative
0
U.S. (TOLL FREE)
+1 (315) 215-3225
Global Treating Chronic Myeloid Leukemia by Phase Market Research Report 2026
Published Date: 2026-02-09
|
Report Code: QYRE-Auto-16I18356
Home | Market Reports | Health| Health Conditions| Cancer
Global Treating Chronic Myeloid Leukemia by Phase Market Research Report 2024
BUY CHAPTERS

Global Treating Chronic Myeloid Leukemia by Phase Market Research Report 2026

Code: QYRE-Auto-16I18356
Report
2026-02-09
Pages:140
QYResearch
Buy Now with 15% Discount
DESCRIPTION
TABLE OF CONTENT
TABLES & FIGURES
FEATURED COMPANIES
Novartis
Bristol–Myers Squibb
Pfizer Inc
Hansoh Pharmaceutical
Takeda Pharmaceuticals
Sun Pharmaceuticals
Mylan NV
Dr. Reddy’s Laboratories
TEVA
Eugia Pharma
Hetero
Sawai Pharmaceutical
Lupin Ltd
Apotex
Chia Tai-Tianqing Pharmaceutical
Qilu Pharmaceutical
CSPC Ouyi Pharmaceutical
Suzhou Thery Pharmaceutical
Lunan Pharmaceutical

Treating Chronic Myeloid Leukemia by Phase Market

The global Treating Chronic Myeloid Leukemia by Phase market was valued at US$ million in 2025 and is anticipated to reach US$ million by 2032, at a CAGR of %from 2026 to 2032.
The treatment of chronic myeloid leukemia (CML) is structured around the disease's phases: chronic, accelerated, and blast. In the chronic phase, first-line therapy typically involves tyrosine kinase inhibitors (TKIs) such as imatinib, dasatinib, or nilotinib. If CML progresses to the accelerated phase, treatment may shift to a different TKI, combination therapies, or clinical trials to manage resistance. In the blast phase, characterized by acute leukemia-like features, more intensive treatments such as chemotherapy or stem cell transplantation are often required.
The North American market for Treating Chronic Myeloid Leukemia by Phase is projected to increase from US$ million in 2025 to US$ million by 2032, at a CAGR of % over 2026–2032.
The Asia-Pacific market for Treating Chronic Myeloid Leukemia by Phase is projected to rise from US$ million in 2025 to US$ million by 2032, at a CAGR of % over 2026–2032.
The global market for Treating Chronic Myeloid Leukemia by Phase in Hospitals is estimated to increase from US$ million in 2025 to US$ million by 2032, at a CAGR of % from 2026 to 2032.
Major global companies of Treating Chronic Myeloid Leukemia by Phase include Novartis, Bristol Myers Squibb, Pfizer, Hansoh Pharmaceutical, Takeda Pharmaceuticals, Sun Pharmaceuticals, Mylan, Dr. Reddy's Laboratories, Teva, Eugia Pharma, etc. In 2025, the world's top three vendors accounted for approximately % of revenue.
This report delivers a comprehensive overview of the global Treating Chronic Myeloid Leukemia by Phase market, with both quantitative and qualitative analyses, to help readers develop growth strategies, assess the competitive landscape, evaluate their position in the current market, and make informed business decisions regarding Treating Chronic Myeloid Leukemia by Phase. The Treating Chronic Myeloid Leukemia by Phase market size, estimates, and forecasts are provided in terms of revenue (US$ millions), with 2025 as the base year and historical and forecast data for 2021–2032.
The report segments the global Treating Chronic Myeloid Leukemia by Phase market comprehensively. Regional market sizes by Type, by Application, , and by player are also provided. For deeper insight, the report profiles the competitive landscape, key competitors, and their respective market rankings, and discusses technological trends and new product developments.
This report will assist Treating Chronic Myeloid Leukemia by Phase manufacturers, new entrants, and companies across the industry value chain with information on revenues, sales volume, and average prices for the overall market and its sub-segments, by company, by Type, by Application, and by region.
Market Segmentation

Scope of Treating Chronic Myeloid Leukemia by Phase Market Report

Report Metric Details
Report Name Treating Chronic Myeloid Leukemia by Phase Market
Segment by Type
  • Chronic Phase
  • Accelerated Phase
  • Blast Phase
Segment by Application
  • Hospitals
  • Clinics
  • Others
By Region
  • North America (United States, Canada)
  • Europe (Germany, France, UK, Italy, Russia) Rest of Europe
  • Nordic Countries
  • Asia-Pacific (China, Japan, South Korea)
  • Southeast Asia (India, Australia)
  • Rest of Asia
  • Latin America (Mexico, Brazil)
  • Rest of Latin America
  • Middle East & Africa (Turkey, Saudi Arabia, UAE, Rest of MEA)
By Company Novartis, Bristol Myers Squibb, Pfizer, Hansoh Pharmaceutical, Takeda Pharmaceuticals, Sun Pharmaceuticals, Mylan, Dr. Reddy's Laboratories, Teva, Eugia Pharma, Hetero, Sawai Pharmaceutical, Lupin, Apotex, Chia Tai Tianqing Pharmaceutical, Qilu Pharmaceutical, CSPC Ouyi Pharmaceutical, Suzhou Thery Pharmaceutical, Lunan Pharmaceutical
Forecast units USD million in value
Report coverage Revenue and volume forecast, company share, competitive landscape, growth factors and trends

Chapter Outline

  • Chapter 1: Defines the scope of the report and presents an executive summary of market segments (by Type, by Application, , etc.), including the size of each segment and its future growth potential. It offers a high-level view of the current market and its likely evolution in the short, medium, and long term.
  • Chapter 2: Summarizes global and regional market size and outlines market dynamics and recent developments, including key drivers, restraints, challenges and risks for industry participants, and relevant policy analysis.
  • Chapter 3: Provides a detailed view of the competitive landscape for Treating Chronic Myeloid Leukemia by Phase companies, covering revenue share, development plans, and mergers and acquisitions.
  • Chapter 4: Analyzes segments by Type, detailing the size and growth potential of each segment to help readers identify blue-ocean opportunities.
  • Chapter 5: Analyzes segments by Application, detailing the size and growth potential of each downstream segment to help readers identify blue-ocean opportunities.
  • Chapter 6–10: Regional deep dives (North America, Europe, Asia Pacific, Latin America, Middle East & Africa) broken down by country. Each chapter quantifies market size and growth potential by region and key countries, and outlines market development, outlook, addressable space, and capacity.
  • Chapter 11: Profiles key players, presenting essential information on leading companies, including product/ service offerings, revenue, gross margin, product introductions/portfolios, recent developments, etc.
  • Chapter 12: Key findings and conclusions of the report.

FAQ for this report

Who are the main players in the Treating Chronic Myeloid Leukemia by Phase Market report?

Ans: The main players in the Treating Chronic Myeloid Leukemia by Phase Market are Novartis, Bristol Myers Squibb, Pfizer, Hansoh Pharmaceutical, Takeda Pharmaceuticals, Sun Pharmaceuticals, Mylan, Dr. Reddy's Laboratories, Teva, Eugia Pharma, Hetero, Sawai Pharmaceutical, Lupin, Apotex, Chia Tai Tianqing Pharmaceutical, Qilu Pharmaceutical, CSPC Ouyi Pharmaceutical, Suzhou Thery Pharmaceutical, Lunan Pharmaceutical

What are the Application segmentation covered in the Treating Chronic Myeloid Leukemia by Phase Market report?

Ans: The Applications covered in the Treating Chronic Myeloid Leukemia by Phase Market report are Hospitals, Clinics, Others

What are the Type segmentation covered in the Treating Chronic Myeloid Leukemia by Phase Market report?

Ans: The Types covered in the Treating Chronic Myeloid Leukemia by Phase Market report are Chronic Phase, Accelerated Phase, Blast Phase

1 Report Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Treating Chronic Myeloid Leukemia by Phase Market Size Growth Rate by Type: 2021 vs 2025 vs 2032
1.2.2 Chronic Phase
1.2.3 Accelerated Phase
1.2.4 Blast Phase
1.3 Market by Application
1.3.1 Global Treating Chronic Myeloid Leukemia by Phase Market Growth by Application: 2021 vs 2025 vs 2032
1.3.2 Hospitals
1.3.3 Clinics
1.3.4 Others
1.4 Assumptions and Limitations
1.5 Study Objectives
1.6 Years Considered
2 Global Growth Trends
2.1 Global Treating Chronic Myeloid Leukemia by Phase Market Perspective (2021–2032)
2.2 Global Treating Chronic Myeloid Leukemia by Phase Growth Trends by Region
2.2.1 Global Treating Chronic Myeloid Leukemia by Phase Market Size by Region: 2021 vs 2025 vs 2032
2.2.2 Treating Chronic Myeloid Leukemia by Phase Historic Market Size by Region (2021–2026)
2.2.3 Treating Chronic Myeloid Leukemia by Phase Forecasted Market Size by Region (2027–2032)
2.3 Treating Chronic Myeloid Leukemia by Phase Market Dynamics
2.3.1 Treating Chronic Myeloid Leukemia by Phase Industry Trends
2.3.2 Treating Chronic Myeloid Leukemia by Phase Market Drivers
2.3.3 Treating Chronic Myeloid Leukemia by Phase Market Challenges
2.3.4 Treating Chronic Myeloid Leukemia by Phase Market Restraints
3 Competition Landscape by Key Players
3.1 Global Top Treating Chronic Myeloid Leukemia by Phase Players by Revenue
3.1.1 Global Top Treating Chronic Myeloid Leukemia by Phase Players by Revenue (2021–2026)
3.1.2 Global Treating Chronic Myeloid Leukemia by Phase Revenue Market Share by Players (2021–2026)
3.2 Global Top Treating Chronic Myeloid Leukemia by Phase Players Market Share by Company Tier (Tier 1, Tier 2, Tier 3)
3.3 Global Key Players Ranking by Treating Chronic Myeloid Leukemia by Phase Revenue
3.4 Global Treating Chronic Myeloid Leukemia by Phase Market Concentration Ratio
3.4.1 Global Treating Chronic Myeloid Leukemia by Phase Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Treating Chronic Myeloid Leukemia by Phase Revenue in 2025
3.5 Global Key Players of Treating Chronic Myeloid Leukemia by Phase Head Offices and Areas Served
3.6 Global Key Players of Treating Chronic Myeloid Leukemia by Phase, Products and Applications
3.7 Global Key Players of Treating Chronic Myeloid Leukemia by Phase, Date of General Availability (GA)
3.8 Mergers and Acquisitions, Expansion Plans
4 Treating Chronic Myeloid Leukemia by Phase Breakdown Data by Type
4.1 Global Treating Chronic Myeloid Leukemia by Phase Historic Market Size by Type (2021–2026)
4.2 Global Treating Chronic Myeloid Leukemia by Phase Forecasted Market Size by Type (2027–2032)
5 Treating Chronic Myeloid Leukemia by Phase Breakdown Data by Application
5.1 Global Treating Chronic Myeloid Leukemia by Phase Historic Market Size by Application (2021–2026)
5.2 Global Treating Chronic Myeloid Leukemia by Phase Forecasted Market Size by Application (2027–2032)
6 North America
6.1 North America Treating Chronic Myeloid Leukemia by Phase Market Size (2021–2032)
6.2 North America Treating Chronic Myeloid Leukemia by Phase Market Growth Rate by Country: 2021 vs 2025 vs 2032
6.3 North America Treating Chronic Myeloid Leukemia by Phase Market Size by Country (2021–2026)
6.4 North America Treating Chronic Myeloid Leukemia by Phase Market Size by Country (2027–2032)
6.5 United States
6.6 Canada
7 Europe
7.1 Europe Treating Chronic Myeloid Leukemia by Phase Market Size (2021–2032)
7.2 Europe Treating Chronic Myeloid Leukemia by Phase Market Growth Rate by Country: 2021 vs 2025 vs 2032
7.3 Europe Treating Chronic Myeloid Leukemia by Phase Market Size by Country (2021–2026)
7.4 Europe Treating Chronic Myeloid Leukemia by Phase Market Size by Country (2027–2032)
7.5 Germany
7.6 France
7.7 U.K.
7.8 Italy
7.9 Russia
7.10 Ireland
8 Asia-Pacific
8.1 Asia-Pacific Treating Chronic Myeloid Leukemia by Phase Market Size (2021–2032)
8.2 Asia-Pacific Treating Chronic Myeloid Leukemia by Phase Market Growth Rate by Region: 2021 vs 2025 vs 2032
8.3 Asia-Pacific Treating Chronic Myeloid Leukemia by Phase Market Size by Region (2021–2026)
8.4 Asia-Pacific Treating Chronic Myeloid Leukemia by Phase Market Size by Region (2027–2032)
8.5 China
8.6 Japan
8.7 South Korea
8.8 Southeast Asia
8.9 India
8.10 Australia & New Zealand
9 Latin America
9.1 Latin America Treating Chronic Myeloid Leukemia by Phase Market Size (2021–2032)
9.2 Latin America Treating Chronic Myeloid Leukemia by Phase Market Growth Rate by Country: 2021 vs 2025 vs 2032
9.3 Latin America Treating Chronic Myeloid Leukemia by Phase Market Size by Country (2021–2026)
9.4 Latin America Treating Chronic Myeloid Leukemia by Phase Market Size by Country (2027–2032)
9.5 Mexico
9.6 Brazil
10 Middle East & Africa
10.1 Middle East & Africa Treating Chronic Myeloid Leukemia by Phase Market Size (2021–2032)
10.2 Middle East & Africa Treating Chronic Myeloid Leukemia by Phase Market Growth Rate by Country: 2021 vs 2025 vs 2032
10.3 Middle East & Africa Treating Chronic Myeloid Leukemia by Phase Market Size by Country (2021–2026)
10.4 Middle East & Africa Treating Chronic Myeloid Leukemia by Phase Market Size by Country (2027–2032)
10.5 Israel
10.6 Saudi Arabia
10.7 UAE
11 Key Players Profiles
11.1 Novartis
11.1.1 Novartis Company Details
11.1.2 Novartis Business Overview
11.1.3 Novartis Treating Chronic Myeloid Leukemia by Phase Introduction
11.1.4 Novartis Revenue in Treating Chronic Myeloid Leukemia by Phase Business (2021–2026)
11.1.5 Novartis Recent Development
11.2 Bristol Myers Squibb
11.2.1 Bristol Myers Squibb Company Details
11.2.2 Bristol Myers Squibb Business Overview
11.2.3 Bristol Myers Squibb Treating Chronic Myeloid Leukemia by Phase Introduction
11.2.4 Bristol Myers Squibb Revenue in Treating Chronic Myeloid Leukemia by Phase Business (2021–2026)
11.2.5 Bristol Myers Squibb Recent Development
11.3 Pfizer
11.3.1 Pfizer Company Details
11.3.2 Pfizer Business Overview
11.3.3 Pfizer Treating Chronic Myeloid Leukemia by Phase Introduction
11.3.4 Pfizer Revenue in Treating Chronic Myeloid Leukemia by Phase Business (2021–2026)
11.3.5 Pfizer Recent Development
11.4 Hansoh Pharmaceutical
11.4.1 Hansoh Pharmaceutical Company Details
11.4.2 Hansoh Pharmaceutical Business Overview
11.4.3 Hansoh Pharmaceutical Treating Chronic Myeloid Leukemia by Phase Introduction
11.4.4 Hansoh Pharmaceutical Revenue in Treating Chronic Myeloid Leukemia by Phase Business (2021–2026)
11.4.5 Hansoh Pharmaceutical Recent Development
11.5 Takeda Pharmaceuticals
11.5.1 Takeda Pharmaceuticals Company Details
11.5.2 Takeda Pharmaceuticals Business Overview
11.5.3 Takeda Pharmaceuticals Treating Chronic Myeloid Leukemia by Phase Introduction
11.5.4 Takeda Pharmaceuticals Revenue in Treating Chronic Myeloid Leukemia by Phase Business (2021–2026)
11.5.5 Takeda Pharmaceuticals Recent Development
11.6 Sun Pharmaceuticals
11.6.1 Sun Pharmaceuticals Company Details
11.6.2 Sun Pharmaceuticals Business Overview
11.6.3 Sun Pharmaceuticals Treating Chronic Myeloid Leukemia by Phase Introduction
11.6.4 Sun Pharmaceuticals Revenue in Treating Chronic Myeloid Leukemia by Phase Business (2021–2026)
11.6.5 Sun Pharmaceuticals Recent Development
11.7 Mylan
11.7.1 Mylan Company Details
11.7.2 Mylan Business Overview
11.7.3 Mylan Treating Chronic Myeloid Leukemia by Phase Introduction
11.7.4 Mylan Revenue in Treating Chronic Myeloid Leukemia by Phase Business (2021–2026)
11.7.5 Mylan Recent Development
11.8 Dr. Reddy's Laboratories
11.8.1 Dr. Reddy's Laboratories Company Details
11.8.2 Dr. Reddy's Laboratories Business Overview
11.8.3 Dr. Reddy's Laboratories Treating Chronic Myeloid Leukemia by Phase Introduction
11.8.4 Dr. Reddy's Laboratories Revenue in Treating Chronic Myeloid Leukemia by Phase Business (2021–2026)
11.8.5 Dr. Reddy's Laboratories Recent Development
11.9 Teva
11.9.1 Teva Company Details
11.9.2 Teva Business Overview
11.9.3 Teva Treating Chronic Myeloid Leukemia by Phase Introduction
11.9.4 Teva Revenue in Treating Chronic Myeloid Leukemia by Phase Business (2021–2026)
11.9.5 Teva Recent Development
11.10 Eugia Pharma
11.10.1 Eugia Pharma Company Details
11.10.2 Eugia Pharma Business Overview
11.10.3 Eugia Pharma Treating Chronic Myeloid Leukemia by Phase Introduction
11.10.4 Eugia Pharma Revenue in Treating Chronic Myeloid Leukemia by Phase Business (2021–2026)
11.10.5 Eugia Pharma Recent Development
11.11 Hetero
11.11.1 Hetero Company Details
11.11.2 Hetero Business Overview
11.11.3 Hetero Treating Chronic Myeloid Leukemia by Phase Introduction
11.11.4 Hetero Revenue in Treating Chronic Myeloid Leukemia by Phase Business (2021–2026)
11.11.5 Hetero Recent Development
11.12 Sawai Pharmaceutical
11.12.1 Sawai Pharmaceutical Company Details
11.12.2 Sawai Pharmaceutical Business Overview
11.12.3 Sawai Pharmaceutical Treating Chronic Myeloid Leukemia by Phase Introduction
11.12.4 Sawai Pharmaceutical Revenue in Treating Chronic Myeloid Leukemia by Phase Business (2021–2026)
11.12.5 Sawai Pharmaceutical Recent Development
11.13 Lupin
11.13.1 Lupin Company Details
11.13.2 Lupin Business Overview
11.13.3 Lupin Treating Chronic Myeloid Leukemia by Phase Introduction
11.13.4 Lupin Revenue in Treating Chronic Myeloid Leukemia by Phase Business (2021–2026)
11.13.5 Lupin Recent Development
11.14 Apotex
11.14.1 Apotex Company Details
11.14.2 Apotex Business Overview
11.14.3 Apotex Treating Chronic Myeloid Leukemia by Phase Introduction
11.14.4 Apotex Revenue in Treating Chronic Myeloid Leukemia by Phase Business (2021–2026)
11.14.5 Apotex Recent Development
11.15 Chia Tai Tianqing Pharmaceutical
11.15.1 Chia Tai Tianqing Pharmaceutical Company Details
11.15.2 Chia Tai Tianqing Pharmaceutical Business Overview
11.15.3 Chia Tai Tianqing Pharmaceutical Treating Chronic Myeloid Leukemia by Phase Introduction
11.15.4 Chia Tai Tianqing Pharmaceutical Revenue in Treating Chronic Myeloid Leukemia by Phase Business (2021–2026)
11.15.5 Chia Tai Tianqing Pharmaceutical Recent Development
11.16 Qilu Pharmaceutical
11.16.1 Qilu Pharmaceutical Company Details
11.16.2 Qilu Pharmaceutical Business Overview
11.16.3 Qilu Pharmaceutical Treating Chronic Myeloid Leukemia by Phase Introduction
11.16.4 Qilu Pharmaceutical Revenue in Treating Chronic Myeloid Leukemia by Phase Business (2021–2026)
11.16.5 Qilu Pharmaceutical Recent Development
11.17 CSPC Ouyi Pharmaceutical
11.17.1 CSPC Ouyi Pharmaceutical Company Details
11.17.2 CSPC Ouyi Pharmaceutical Business Overview
11.17.3 CSPC Ouyi Pharmaceutical Treating Chronic Myeloid Leukemia by Phase Introduction
11.17.4 CSPC Ouyi Pharmaceutical Revenue in Treating Chronic Myeloid Leukemia by Phase Business (2021–2026)
11.17.5 CSPC Ouyi Pharmaceutical Recent Development
11.18 Suzhou Thery Pharmaceutical
11.18.1 Suzhou Thery Pharmaceutical Company Details
11.18.2 Suzhou Thery Pharmaceutical Business Overview
11.18.3 Suzhou Thery Pharmaceutical Treating Chronic Myeloid Leukemia by Phase Introduction
11.18.4 Suzhou Thery Pharmaceutical Revenue in Treating Chronic Myeloid Leukemia by Phase Business (2021–2026)
11.18.5 Suzhou Thery Pharmaceutical Recent Development
11.19 Lunan Pharmaceutical
11.19.1 Lunan Pharmaceutical Company Details
11.19.2 Lunan Pharmaceutical Business Overview
11.19.3 Lunan Pharmaceutical Treating Chronic Myeloid Leukemia by Phase Introduction
11.19.4 Lunan Pharmaceutical Revenue in Treating Chronic Myeloid Leukemia by Phase Business (2021–2026)
11.19.5 Lunan Pharmaceutical Recent Development
12 Analyst's Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.1.1 Research Programs/Design
13.1.1.2 Market Size Estimation
13.1.1.3 Market Breakdown and Data Triangulation
13.1.2 Data Source
13.1.2.1 Secondary Sources
13.1.2.2 Primary Sources
13.2 Author Details
13.3 Disclaimer
FEATURED COMPANIES
Novartis
Bristol–Myers Squibb
Pfizer Inc
Hansoh Pharmaceutical
Takeda Pharmaceuticals
Sun Pharmaceuticals
Mylan NV
Dr. Reddy’s Laboratories
TEVA
Eugia Pharma
Hetero
Sawai Pharmaceutical
Lupin Ltd
Apotex
Chia Tai-Tianqing Pharmaceutical
Qilu Pharmaceutical
CSPC Ouyi Pharmaceutical
Suzhou Thery Pharmaceutical
Lunan Pharmaceutical
List of Tables
 Table 1. Global Treating Chronic Myeloid Leukemia by Phase Market Size Growth Rate by Type (US$ Million): 2021 vs 2025 vs 2032
 Table 2. Key Players of Chronic Phase
 Table 3. Key Players of Accelerated Phase
 Table 4. Key Players of Blast Phase
 Table 5. Global Treating Chronic Myeloid Leukemia by Phase Market Size Growth by Application (US$ Million): 2021 vs 2025 vs 2032
 Table 6. Global Treating Chronic Myeloid Leukemia by Phase Market Size by Region (US$ Million): 2021 vs 2025 vs 2032
 Table 7. Global Treating Chronic Myeloid Leukemia by Phase Market Size by Region (US$ Million), 2021–2026
 Table 8. Global Treating Chronic Myeloid Leukemia by Phase Market Share by Region (2021–2026)
 Table 9. Global Treating Chronic Myeloid Leukemia by Phase Forecasted Market Size by Region (US$ Million), 2027–2032
 Table 10. Global Treating Chronic Myeloid Leukemia by Phase Market Share by Region (2027–2032)
 Table 11. Treating Chronic Myeloid Leukemia by Phase Market Trends
 Table 12. Treating Chronic Myeloid Leukemia by Phase Market Drivers
 Table 13. Treating Chronic Myeloid Leukemia by Phase Market Challenges
 Table 14. Treating Chronic Myeloid Leukemia by Phase Market Restraints
 Table 15. Global Treating Chronic Myeloid Leukemia by Phase Revenue by Players (US$ Million), 2021–2026
 Table 16. Global Treating Chronic Myeloid Leukemia by Phase Market Share by Players (2021–2026)
 Table 17. Global Top Treating Chronic Myeloid Leukemia by Phase Players by Tier (Tier 1, Tier 2, and Tier 3), based on Treating Chronic Myeloid Leukemia by Phase Revenue, 2025
 Table 18. Ranking of Global Top Treating Chronic Myeloid Leukemia by Phase Companies by Revenue (US$ Million) in 2025
 Table 19. Global 5 Largest Players Market Share by Treating Chronic Myeloid Leukemia by Phase Revenue (CR5 and HHI), 2021–2026
 Table 20. Global Key Players of Treating Chronic Myeloid Leukemia by Phase, Headquarters and Area Served
 Table 21. Global Key Players of Treating Chronic Myeloid Leukemia by Phase, Products and Applications
 Table 22. Global Key Players of Treating Chronic Myeloid Leukemia by Phase, Date of General Availability (GA)
 Table 23. Mergers and Acquisitions, Expansion Plans
 Table 24. Global Treating Chronic Myeloid Leukemia by Phase Market Size by Type (US$ Million), 2021–2026
 Table 25. Global Treating Chronic Myeloid Leukemia by Phase Revenue Market Share by Type (2021–2026)
 Table 26. Global Treating Chronic Myeloid Leukemia by Phase Forecasted Market Size by Type (US$ Million), 2027–2032
 Table 27. Global Treating Chronic Myeloid Leukemia by Phase Revenue Market Share by Type (2027–2032)
 Table 28. Global Treating Chronic Myeloid Leukemia by Phase Market Size by Application (US$ Million), 2021–2026
 Table 29. Global Treating Chronic Myeloid Leukemia by Phase Revenue Market Share by Application (2021–2026)
 Table 30. Global Treating Chronic Myeloid Leukemia by Phase Forecasted Market Size by Application (US$ Million), 2027–2032
 Table 31. Global Treating Chronic Myeloid Leukemia by Phase Revenue Market Share by Application (2027–2032)
 Table 32. North America Treating Chronic Myeloid Leukemia by Phase Market Size Growth Rate by Country (US$ Million): 2021 vs 2025 vs 2032
 Table 33. North America Treating Chronic Myeloid Leukemia by Phase Market Size by Country (US$ Million), 2021–2026
 Table 34. North America Treating Chronic Myeloid Leukemia by Phase Market Size by Country (US$ Million), 2027–2032
 Table 35. Europe Treating Chronic Myeloid Leukemia by Phase Market Size Growth Rate by Country (US$ Million): 2021 vs 2025 vs 2032
 Table 36. Europe Treating Chronic Myeloid Leukemia by Phase Market Size by Country (US$ Million), 2021–2026
 Table 37. Europe Treating Chronic Myeloid Leukemia by Phase Market Size by Country (US$ Million), 2027–2032
 Table 38. Asia-Pacific Treating Chronic Myeloid Leukemia by Phase Market Size Growth Rate by Region (US$ Million): 2021 vs 2025 vs 2032
 Table 39. Asia-Pacific Treating Chronic Myeloid Leukemia by Phase Market Size by Region (US$ Million), 2021–2026
 Table 40. Asia-Pacific Treating Chronic Myeloid Leukemia by Phase Market Size by Region (US$ Million), 2027–2032
 Table 41. Latin America Treating Chronic Myeloid Leukemia by Phase Market Size Growth Rate by Country (US$ Million): 2021 vs 2025 vs 2032
 Table 42. Latin America Treating Chronic Myeloid Leukemia by Phase Market Size by Country (US$ Million), 2021–2026
 Table 43. Latin America Treating Chronic Myeloid Leukemia by Phase Market Size by Country (US$ Million), 2027–2032
 Table 44. Middle East & Africa Treating Chronic Myeloid Leukemia by Phase Market Size Growth Rate by Country (US$ Million): 2021 vs 2025 vs 2032
 Table 45. Middle East & Africa Treating Chronic Myeloid Leukemia by Phase Market Size by Country (US$ Million), 2021–2026
 Table 46. Middle East & Africa Treating Chronic Myeloid Leukemia by Phase Market Size by Country (US$ Million), 2027–2032
 Table 47. Novartis Company Details
 Table 48. Novartis Business Overview
 Table 49. Novartis Treating Chronic Myeloid Leukemia by Phase Product
 Table 50. Novartis Revenue in Treating Chronic Myeloid Leukemia by Phase Business (US$ Million), 2021–2026
 Table 51. Novartis Recent Development
 Table 52. Bristol Myers Squibb Company Details
 Table 53. Bristol Myers Squibb Business Overview
 Table 54. Bristol Myers Squibb Treating Chronic Myeloid Leukemia by Phase Product
 Table 55. Bristol Myers Squibb Revenue in Treating Chronic Myeloid Leukemia by Phase Business (US$ Million), 2021–2026
 Table 56. Bristol Myers Squibb Recent Development
 Table 57. Pfizer Company Details
 Table 58. Pfizer Business Overview
 Table 59. Pfizer Treating Chronic Myeloid Leukemia by Phase Product
 Table 60. Pfizer Revenue in Treating Chronic Myeloid Leukemia by Phase Business (US$ Million), 2021–2026
 Table 61. Pfizer Recent Development
 Table 62. Hansoh Pharmaceutical Company Details
 Table 63. Hansoh Pharmaceutical Business Overview
 Table 64. Hansoh Pharmaceutical Treating Chronic Myeloid Leukemia by Phase Product
 Table 65. Hansoh Pharmaceutical Revenue in Treating Chronic Myeloid Leukemia by Phase Business (US$ Million), 2021–2026
 Table 66. Hansoh Pharmaceutical Recent Development
 Table 67. Takeda Pharmaceuticals Company Details
 Table 68. Takeda Pharmaceuticals Business Overview
 Table 69. Takeda Pharmaceuticals Treating Chronic Myeloid Leukemia by Phase Product
 Table 70. Takeda Pharmaceuticals Revenue in Treating Chronic Myeloid Leukemia by Phase Business (US$ Million), 2021–2026
 Table 71. Takeda Pharmaceuticals Recent Development
 Table 72. Sun Pharmaceuticals Company Details
 Table 73. Sun Pharmaceuticals Business Overview
 Table 74. Sun Pharmaceuticals Treating Chronic Myeloid Leukemia by Phase Product
 Table 75. Sun Pharmaceuticals Revenue in Treating Chronic Myeloid Leukemia by Phase Business (US$ Million), 2021–2026
 Table 76. Sun Pharmaceuticals Recent Development
 Table 77. Mylan Company Details
 Table 78. Mylan Business Overview
 Table 79. Mylan Treating Chronic Myeloid Leukemia by Phase Product
 Table 80. Mylan Revenue in Treating Chronic Myeloid Leukemia by Phase Business (US$ Million), 2021–2026
 Table 81. Mylan Recent Development
 Table 82. Dr. Reddy's Laboratories Company Details
 Table 83. Dr. Reddy's Laboratories Business Overview
 Table 84. Dr. Reddy's Laboratories Treating Chronic Myeloid Leukemia by Phase Product
 Table 85. Dr. Reddy's Laboratories Revenue in Treating Chronic Myeloid Leukemia by Phase Business (US$ Million), 2021–2026
 Table 86. Dr. Reddy's Laboratories Recent Development
 Table 87. Teva Company Details
 Table 88. Teva Business Overview
 Table 89. Teva Treating Chronic Myeloid Leukemia by Phase Product
 Table 90. Teva Revenue in Treating Chronic Myeloid Leukemia by Phase Business (US$ Million), 2021–2026
 Table 91. Teva Recent Development
 Table 92. Eugia Pharma Company Details
 Table 93. Eugia Pharma Business Overview
 Table 94. Eugia Pharma Treating Chronic Myeloid Leukemia by Phase Product
 Table 95. Eugia Pharma Revenue in Treating Chronic Myeloid Leukemia by Phase Business (US$ Million), 2021–2026
 Table 96. Eugia Pharma Recent Development
 Table 97. Hetero Company Details
 Table 98. Hetero Business Overview
 Table 99. Hetero Treating Chronic Myeloid Leukemia by Phase Product
 Table 100. Hetero Revenue in Treating Chronic Myeloid Leukemia by Phase Business (US$ Million), 2021–2026
 Table 101. Hetero Recent Development
 Table 102. Sawai Pharmaceutical Company Details
 Table 103. Sawai Pharmaceutical Business Overview
 Table 104. Sawai Pharmaceutical Treating Chronic Myeloid Leukemia by Phase Product
 Table 105. Sawai Pharmaceutical Revenue in Treating Chronic Myeloid Leukemia by Phase Business (US$ Million), 2021–2026
 Table 106. Sawai Pharmaceutical Recent Development
 Table 107. Lupin Company Details
 Table 108. Lupin Business Overview
 Table 109. Lupin Treating Chronic Myeloid Leukemia by Phase Product
 Table 110. Lupin Revenue in Treating Chronic Myeloid Leukemia by Phase Business (US$ Million), 2021–2026
 Table 111. Lupin Recent Development
 Table 112. Apotex Company Details
 Table 113. Apotex Business Overview
 Table 114. Apotex Treating Chronic Myeloid Leukemia by Phase Product
 Table 115. Apotex Revenue in Treating Chronic Myeloid Leukemia by Phase Business (US$ Million), 2021–2026
 Table 116. Apotex Recent Development
 Table 117. Chia Tai Tianqing Pharmaceutical Company Details
 Table 118. Chia Tai Tianqing Pharmaceutical Business Overview
 Table 119. Chia Tai Tianqing Pharmaceutical Treating Chronic Myeloid Leukemia by Phase Product
 Table 120. Chia Tai Tianqing Pharmaceutical Revenue in Treating Chronic Myeloid Leukemia by Phase Business (US$ Million), 2021–2026
 Table 121. Chia Tai Tianqing Pharmaceutical Recent Development
 Table 122. Qilu Pharmaceutical Company Details
 Table 123. Qilu Pharmaceutical Business Overview
 Table 124. Qilu Pharmaceutical Treating Chronic Myeloid Leukemia by Phase Product
 Table 125. Qilu Pharmaceutical Revenue in Treating Chronic Myeloid Leukemia by Phase Business (US$ Million), 2021–2026
 Table 126. Qilu Pharmaceutical Recent Development
 Table 127. CSPC Ouyi Pharmaceutical Company Details
 Table 128. CSPC Ouyi Pharmaceutical Business Overview
 Table 129. CSPC Ouyi Pharmaceutical Treating Chronic Myeloid Leukemia by Phase Product
 Table 130. CSPC Ouyi Pharmaceutical Revenue in Treating Chronic Myeloid Leukemia by Phase Business (US$ Million), 2021–2026
 Table 131. CSPC Ouyi Pharmaceutical Recent Development
 Table 132. Suzhou Thery Pharmaceutical Company Details
 Table 133. Suzhou Thery Pharmaceutical Business Overview
 Table 134. Suzhou Thery Pharmaceutical Treating Chronic Myeloid Leukemia by Phase Product
 Table 135. Suzhou Thery Pharmaceutical Revenue in Treating Chronic Myeloid Leukemia by Phase Business (US$ Million), 2021–2026
 Table 136. Suzhou Thery Pharmaceutical Recent Development
 Table 137. Lunan Pharmaceutical Company Details
 Table 138. Lunan Pharmaceutical Business Overview
 Table 139. Lunan Pharmaceutical Treating Chronic Myeloid Leukemia by Phase Product
 Table 140. Lunan Pharmaceutical Revenue in Treating Chronic Myeloid Leukemia by Phase Business (US$ Million), 2021–2026
 Table 141. Lunan Pharmaceutical Recent Development
 Table 142. Research Programs/Design for This Report
 Table 143. Key Data Information from Secondary Sources
 Table 144. Key Data Information from Primary Sources
 Table 145. Authors List of This Report


List of Figures
 Figure 1. Treating Chronic Myeloid Leukemia by Phase Picture
 Figure 2. Global Treating Chronic Myeloid Leukemia by Phase Market Size Comparison by Type (US$ Million), 2021–2032
 Figure 3. Global Treating Chronic Myeloid Leukemia by Phase Market Share by Type: 2025 vs 2032
 Figure 4. Chronic Phase Features
 Figure 5. Accelerated Phase Features
 Figure 6. Blast Phase Features
 Figure 7. Global Treating Chronic Myeloid Leukemia by Phase Market Size by Application (US$ Million), 2021–2032
 Figure 8. Global Treating Chronic Myeloid Leukemia by Phase Market Share by Application: 2025 vs 2032
 Figure 9. Hospitals Case Studies
 Figure 10. Clinics Case Studies
 Figure 11. Others Case Studies
 Figure 12. Treating Chronic Myeloid Leukemia by Phase Report Years Considered
 Figure 13. Global Treating Chronic Myeloid Leukemia by Phase Market Size (US$ Million), Year-over-Year: 2021–2032
 Figure 14. Global Treating Chronic Myeloid Leukemia by Phase Market Size, (US$ Million), 2021 vs 2025 vs 2032
 Figure 15. Global Treating Chronic Myeloid Leukemia by Phase Market Share by Region: 2025 vs 2032
 Figure 16. Global Treating Chronic Myeloid Leukemia by Phase Market Share by Players in 2025
 Figure 17. Global Treating Chronic Myeloid Leukemia by Phase Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
 Figure 18. The Top 10 and 5 Players Market Share by Treating Chronic Myeloid Leukemia by Phase Revenue in 2025
 Figure 19. North America Treating Chronic Myeloid Leukemia by Phase Market Size YoY Growth (US$ Million), 2021–2032
 Figure 20. North America Treating Chronic Myeloid Leukemia by Phase Market Share by Country (2021–2032)
 Figure 21. United States Treating Chronic Myeloid Leukemia by Phase Market Size YoY Growth (US$ Million), 2021–2032
 Figure 22. Canada Treating Chronic Myeloid Leukemia by Phase Market Size YoY Growth (US$ Million), 2021–2032
 Figure 23. Europe Treating Chronic Myeloid Leukemia by Phase Market Size YoY Growth (US$ Million), 2021–2032
 Figure 24. Europe Treating Chronic Myeloid Leukemia by Phase Market Share by Country (2021–2032)
 Figure 25. Germany Treating Chronic Myeloid Leukemia by Phase Market Size YoY Growth (US$ Million), 2021–2032
 Figure 26. France Treating Chronic Myeloid Leukemia by Phase Market Size YoY Growth (US$ Million), 2021–2032
 Figure 27. U.K. Treating Chronic Myeloid Leukemia by Phase Market Size YoY Growth (US$ Million), 2021–2032
 Figure 28. Italy Treating Chronic Myeloid Leukemia by Phase Market Size YoY Growth (US$ Million), 2021–2032
 Figure 29. Russia Treating Chronic Myeloid Leukemia by Phase Market Size YoY Growth (US$ Million), 2021–2032
 Figure 30. Ireland Treating Chronic Myeloid Leukemia by Phase Market Size YoY Growth (US$ Million), 2021–2032
 Figure 31. Asia-Pacific Treating Chronic Myeloid Leukemia by Phase Market Size YoY Growth (US$ Million), 2021–2032
 Figure 32. Asia-Pacific Treating Chronic Myeloid Leukemia by Phase Market Share by Region (2021–2032)
 Figure 33. China Treating Chronic Myeloid Leukemia by Phase Market Size YoY Growth (US$ Million), 2021–2032
 Figure 34. Japan Treating Chronic Myeloid Leukemia by Phase Market Size YoY Growth (US$ Million), 2021–2032
 Figure 35. South Korea Treating Chronic Myeloid Leukemia by Phase Market Size YoY Growth (US$ Million), 2021–2032
 Figure 36. Southeast Asia Treating Chronic Myeloid Leukemia by Phase Market Size YoY Growth (US$ Million), 2021–2032
 Figure 37. India Treating Chronic Myeloid Leukemia by Phase Market Size YoY Growth (US$ Million), 2021–2032
 Figure 38. Australia & New Zealand Treating Chronic Myeloid Leukemia by Phase Market Size YoY Growth (US$ Million), 2021–2032
 Figure 39. Latin America Treating Chronic Myeloid Leukemia by Phase Market Size YoY Growth (US$ Million), 2021–2032
 Figure 40. Latin America Treating Chronic Myeloid Leukemia by Phase Market Share by Country (2021–2032)
 Figure 41. Mexico Treating Chronic Myeloid Leukemia by Phase Market Size YoY Growth (US$ Million), 2021–2032
 Figure 42. Brazil Treating Chronic Myeloid Leukemia by Phase Market Size YoY Growth (US$ Million), 2021–2032
 Figure 43. Middle East & Africa Treating Chronic Myeloid Leukemia by Phase Market Size YoY Growth (US$ Million), 2021–2032
 Figure 44. Middle East & Africa Treating Chronic Myeloid Leukemia by Phase Market Share by Country (2021–2032)
 Figure 45. Israel Treating Chronic Myeloid Leukemia by Phase Market Size YoY Growth (US$ Million), 2021–2032
 Figure 46. Saudi Arabia Treating Chronic Myeloid Leukemia by Phase Market Size YoY Growth (US$ Million), 2021–2032
 Figure 47. UAE Treating Chronic Myeloid Leukemia by Phase Market Size YoY Growth (US$ Million), 2021–2032
 Figure 48. Novartis Revenue Growth Rate in Treating Chronic Myeloid Leukemia by Phase Business (2021–2026)
 Figure 49. Bristol Myers Squibb Revenue Growth Rate in Treating Chronic Myeloid Leukemia by Phase Business (2021–2026)
 Figure 50. Pfizer Revenue Growth Rate in Treating Chronic Myeloid Leukemia by Phase Business (2021–2026)
 Figure 51. Hansoh Pharmaceutical Revenue Growth Rate in Treating Chronic Myeloid Leukemia by Phase Business (2021–2026)
 Figure 52. Takeda Pharmaceuticals Revenue Growth Rate in Treating Chronic Myeloid Leukemia by Phase Business (2021–2026)
 Figure 53. Sun Pharmaceuticals Revenue Growth Rate in Treating Chronic Myeloid Leukemia by Phase Business (2021–2026)
 Figure 54. Mylan Revenue Growth Rate in Treating Chronic Myeloid Leukemia by Phase Business (2021–2026)
 Figure 55. Dr. Reddy's Laboratories Revenue Growth Rate in Treating Chronic Myeloid Leukemia by Phase Business (2021–2026)
 Figure 56. Teva Revenue Growth Rate in Treating Chronic Myeloid Leukemia by Phase Business (2021–2026)
 Figure 57. Eugia Pharma Revenue Growth Rate in Treating Chronic Myeloid Leukemia by Phase Business (2021–2026)
 Figure 58. Hetero Revenue Growth Rate in Treating Chronic Myeloid Leukemia by Phase Business (2021–2026)
 Figure 59. Sawai Pharmaceutical Revenue Growth Rate in Treating Chronic Myeloid Leukemia by Phase Business (2021–2026)
 Figure 60. Lupin Revenue Growth Rate in Treating Chronic Myeloid Leukemia by Phase Business (2021–2026)
 Figure 61. Apotex Revenue Growth Rate in Treating Chronic Myeloid Leukemia by Phase Business (2021–2026)
 Figure 62. Chia Tai Tianqing Pharmaceutical Revenue Growth Rate in Treating Chronic Myeloid Leukemia by Phase Business (2021–2026)
 Figure 63. Qilu Pharmaceutical Revenue Growth Rate in Treating Chronic Myeloid Leukemia by Phase Business (2021–2026)
 Figure 64. CSPC Ouyi Pharmaceutical Revenue Growth Rate in Treating Chronic Myeloid Leukemia by Phase Business (2021–2026)
 Figure 65. Suzhou Thery Pharmaceutical Revenue Growth Rate in Treating Chronic Myeloid Leukemia by Phase Business (2021–2026)
 Figure 66. Lunan Pharmaceutical Revenue Growth Rate in Treating Chronic Myeloid Leukemia by Phase Business (2021–2026)
 Figure 67. Bottom-up and Top-down Approaches for This Report
 Figure 68. Data Triangulation
 Figure 69. Key Executives Interviewed
SELECT A FORMAT
Added to Cart
Electronic

$2900

Single User License
Electronic

$4350

Multi User License
Electronic

$5800

Enterprise License
Add to Cart
Buy Now (15% Discount)
INQUIRE FOR DISCOUNT

HAVE A QUERY?

INQUIRE ABOUT REPORT EMAIL US

OUR CUSTOMER

Leap India

SIMILAR REPORTS

Global Treatment for Accelerated Phase CML Market Research Report 2024
Global Treatment of Blastic Phase CML Market Research Report 2024
Global TKI for Chronic Myeloid Leukemia Market Research Report 2024
Global Chronic Myeloid Leukemia Treatment Drugs Market Research Report 2025
Global Chronic Myeloid Leukemia CML Treatment Market Insights Forecast to 2030
Global Leukemia Targeted Therapy Drugs Market Research Report 2024
Global Targeted Therapy Drugs for Leukemia Market Research Report 2024
Global Dasatinib API Market Research Report 2024
Global Targeted Drug for Leukemia Market Research Report 2024
Global Targeted Drug for Blood Cancers Market Research Report 2024
Imatinib Drug Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030
Global MET TKIs Market Research Report 2024
Global Ponatinib Tablets Market Research Report 2024
Nilotinib Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030
Global EGFR TKI for Advanced NSCLC Market Research Report 2024
Global TKIs for Breast Cancer Market Research Report 2024
Global Ponatinib HCl Market Research Report 2024
Ponatinib Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030
Ponatinib Drugs Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030
Global Chronic Lymphocytic Leukemia CLL Treatment Market Insights Forecast to 2030
Call
Buy Now
REQUEST FREE SAMPLE REPORT
Support Contacts
U.S. (TOLL FREE)
+1 (425) 388-2538
THE COMPANY
OUR PRODUCTS
CUSTOMER SUPPORT
POLICES
THE COMPANY
CUSTOMER SUPPORT
OUR PRODUCTS
POLICES
Copyright © 2018 Valuates.com. All Rights Reserved.
Sitemap - Privacy Policy - Terms & Conditions